中国临床药理学杂志Issue(3)：267-269,3.DOI:10.13699/j.cnki.1001-6821.2016.03.023
细胞色素 P4502 C19基因多态性对健康受试者伏立康唑药代动力学影响的系统评价
Effect of cytochrome P450 2C19 genotype on pharmacokinetics of vorivonazole in healthy volunteers:A systematic review and meta-analysis
李晓菲 1于彩媛 2程毅 1牛天巍 3陈恳 1唐惠林4
作者信息
- 1. 北京大学 第三医院 药剂科，北京 100191
- 2. 哈尔滨医科大学 附属第一医院，哈尔滨150001
- 3. 国家开放大学，北京 100039
- 4. 新疆医科大学 第一附属医院 药物临床试验机构，乌鲁木齐 830011
- 折叠
摘要
Abstract
Objective To evaluate effect of cytochrome P450 2C19 ( CYP2 C19 ) genotype on pharmacokinetics of voriconazole in healthy volunteers. Methods Studies evaluating the CYP2C19 genetic polymorphism and pharmacokinetics of voriconazole were retrieved through a systematical search of electronic databases ( up to Feb.2015 ).Studies selection according to the inclusion criteria , data extraction and risk of bias assessment were conducted.The meta -analysis was performed using RevMan 5.0.Results Nine studies were included in this meta -analysis, 8 in English, 1 in Chinese.CYP2C19 gene polymorphism had a significantly effect on AUC , poor metabolizers ( PM)>intermediate metabolizers ( HEM ) >extensive metabolizers (EM) >ultrarapid metabolizers (UM), CL(EM>HEM>PM), Cmax ( PM >HEM, EM >UM ) , t1/2 ( PM >EM, PM >HEM ) and tmax ( PM>EM,HEM>EM).Conclusion The pharmacokinetics parameters of voriconazole were influenced significantly by CYP 2C19 genotype in healthy volunteers.关键词
伏立康唑/细胞色素P4502 C19/药代动力学/基因多态性Key words
voriconazole/cytochrome P450 2 C19/pharmacokinetic/gene polymorphism分类
医药卫生引用本文复制引用
李晓菲,于彩媛,程毅,牛天巍,陈恳,唐惠林..细胞色素 P4502 C19基因多态性对健康受试者伏立康唑药代动力学影响的系统评价[J].中国临床药理学杂志,2016,(3):267-269,3.
